CSI Focus Workshop

TAVI

Thursday june 27, 2019

Transcatheter aortic valve implantation (TAVI) has become the most common structural intervention in adult cardiology, with the annual number of TAVIs surpassing the number of conventional aortic valve replacement in many countries. Transcatheter technology has improved at a rapid pace and has allowed aortic valve implantations with low rates of complications. Nevertheless, a number of clinical and technical challenges remain. For example, the best approach to bicuspid aortic valves, asymptomatic severe aortic stenosis, moderate aortic stenosis in the setting of a reduced left ventricular systolic function, severe aortic stenosis in low surgical risk patients and pure aortic regurgitation has yet to be determined. Furthermore, cerebral protection strategies are evolving and the best post-procedural antiplatelet and anticoagulant therapy are being evaluated. Finally, though less common in the current era, complications such as residual paravalvar regurgitation, valve thrombus, coronary occlusion, complete heart block and vascular injury continue to occur.

CSI 2019 will be holding a comprehensive TAVI workshop on Thursday, June 27, that will review the role of TAVI for the treatment of aortic valve disease, address aforementioned challenges, provide an overview of novel technologies and showcase experienced operators during live case transmissions.